Company: BWAY
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001171843-25-002347
Chunk: 1

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: 20-F
Item: Item 5
Chunk 1
---
Item
5. Operating and Financial Review and Prospects

” and elsewhere in this Annual Report may include forward-looking statements.
These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements by terms including “anticipates,” “believes,” “could,”
“estimates,” “expects,” “intends,” “may,” “plans,” “potential,”
“predicts,” “projects,” “should,” “will,” “would,” and similar expressions
intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and
are based on assumptions and subject to risks and uncertainties. You should not put undue reliance on any forward-looking statements.
Unless we are required to do so under U. S. federal securities laws or other applicable laws, we do not intend to update or revise any
forward-looking statements.

   1  

Factors that could cause our actual results to differ
materially from those expressed or implied in such forward-looking statements include, but are not limited to:

  market perception and acceptance of Deep Transcranial Magnetic Stimulation, or Deep                    

  availability of reimbursement from third-party payors, including insurance companies  

  the adequacy of our existing capital to meet our future capital requirements;  

  our ability to commercialize Deep TMS, including internationally, by ourselves or through  

  our ability to develop enhancements to our Deep TMS system through our research and  

  our reliance on third parties to conduct our clinical trials and manufacture our product  

  our ability to complete and obtain favorable results from existing clinical trials,     

  our ability to obtain and comply with regulatory approvals of Deep TMS and enhancements  

  our ability to obtain and maintain adequate protection of our intellectual property,  

  our ability to operate within the changing market conditions caused by geopolitical   

  ITEM 1.      IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS  
 ──────────────────────────────────────────────────────────────────────

Not applicable.

  ITEM 2.      OFFER STATISTICS AND EXPECTED TIMETABLE  
 ────────────────────────────────────────────────────────

Not applicable.

  ITEM 3.      KEY INFORMATION  
 ────────────────────────────────

  [Reserved]  

  Capitalization and Indebtedness  
 ─────────